GRB2 and hepatocellular carcinoma: Specifically, alterations in the expression of genes related to TGF-β signaling, including CDKN2B, GRB2, and PIK3R1, in CTCs emerged as potential novel biomarkers for predicting early therapeutic response to Atezo+Bev in patients with unresectable HCC.